Insider Trades
News
globenewswire.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 17
globenewswire.comZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summitglobenewswire.comJun 11
globenewswire.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicineglobenewswire.comJun 2
globenewswire.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicineglobenewswire.comJun 2
globenewswire.comZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RDglobenewswire.comMay 28